Sign In

Su-Lin Lee

Senior Manager, Regulatory CMC

Overview

Su-Lin Lee, Ph.D., RAC, is a highly accomplished regulatory affairs professional with over seven years of expertise in navigating the complex landscape of regulatory requirements in the United States, Europe, and global regulatory affairs. With a distinguished background in drug discovery research spanning over eleven years in diverse therapeutic areas, Su-Lin has demonstrated exceptional capability in aligning regulatory frameworks with innovative drug development strategies. Her comprehensive understanding of current regulatory policy priorities positions her as a vital asset in the pharmaceutical industry.

Professional Background

Dr. Lee currently serves as the Senior Manager of Regulatory Chemistry, Manufacturing, and Controls (CMC) at Mirati Therapeutics, a leading biopharmaceutical company dedicated to discovering and developing transformative medicines for people with cancer. In this role, she applies her extensive regulatory knowledge to ensure that products meet stringent regulatory standards while advancing the company's mission to deliver novel therapies.

Her previous positions at the U.S. Food and Drug Administration (FDA) have provided her with invaluable insights and experience. As a CMC Reviewer and later as Acting Science Informatics Team Lead at the FDA Office of New Drug Products, Dr. Lee contributed to the evaluation and approval of numerous New Drug Applications (NDAs) and Investigational New Drug (IND) submissions. Her tenure at the FDA has solidified her reputation as a knowledgeable advocate for public health and industry innovation.

Prior to her critical work at the FDA, Su-Lin's research background as a Postdoctoral Research Fellow at the National Institutes of Health (NIH) honed her scientific inquiry and regulatory acumen, equipping her for her successful career in regulatory affairs. Her experience as a Graduate Research Associate at The Ohio State University and a Graduate Research Assistant at National Taiwan University laid a strong foundation for her scientific expertise.

Education and Achievements

Dr. Lee earned her Ph.D. in Medicinal Chemistry from The Ohio State University, where she engaged in advanced research that focused on the design and development of therapeutic agents. Her academic journey also includes a Master's degree in Pharmacy from National Taiwan University, where she gained vital skills in pharmaceutical sciences. She completed her Bachelor's Degree in Chemistry at National Chung Cheng University, further enhancing her understanding of chemical processes and drug formulation.

In recognition of her proficiency in regulatory affairs, Su-Lin successfully obtained the Regulatory Affairs Certification (RAC) for drugs, validating her extensive knowledge of regulatory policies and priorities within therapeutic contexts. This certification not only demonstrates her dedication to her profession but also underscores her commitment to staying abreast of evolving regulatory landscapes.

Throughout her career, Su-Lin has developed a keen understanding of the regulatory requirements necessary to bring innovative therapies from concept to market. Her expertise in drug discovery informs her regulatory approach, helping to bridge the gap between scientific innovation and regulatory compliance. By ensuring rigorous standards are met, she contributes significantly to public health outcomes and the advancement of medical science.

Achievements

Dr. Lee's career achievements reveal a robust profile marked by her significant contributions to regulatory affairs and drug discovery research. Some notable highlights include:

  • Successfully managing and leading regulatory submissions at Mirati Therapeutics, resulting in expedited development timelines for new cancer therapies.
  • Playing a pivotal role in the review and approval process of New Drug Applications during her time at the FDA, influencing drug availability for patients and healthcare providers.
  • Leading initiatives in science informatics that improved the efficiency and effectiveness of regulatory processes at the FDA.
  • Conducting groundbreaking research during her tenure at the NIH that has contributed to the broader scientific community's understanding of medicinal chemistry.

Throughout her impressive career, Su-Lin Lee has demonstrated an unwavering commitment to excellence in all her professional endeavors. Her extensive education and practical experience position her as a leading expert in regulatory affairs, dedicated to improving patient outcomes through innovative therapeutic solutions.

Related Questions

How did Su-Lin Lee, Ph.D., develop her extensive expertise in regulatory affairs and drug discovery?
In what ways has Dr. Su-Lin Lee contributed to the advancement of cancer therapies at Mirati Therapeutics?
What challenges did Su-Lin Lee face while working at the FDA and how did she overcome them?
How has Su-Lin Lee's academic background shaped her career in drug regulatory affairs?
What are the implications of Su-Lin Lee's work for the future of drug development and patient safety?
Su-Lin Lee
Add to my network

Location

San Diego, California, United States